Carisoprodol Impurity B

FTIR assay method for UV inactive drug carisoprodol and identification of degradants by RP-HPLC and ESI-MS
Pratap Chandra Acharya∗, Ruqaiya Vasi, Divya Suares
Journal of Chromatography B Volumes 1029–1030, 1 September 2016, Pages 16-21
 
A Comparative Study of HPLC-UV and UPLC-DAD Methods for Simultaneous Estimation of Aspirin and Cilostazol in the Presence of Their Related Impurities in Bulk and Capsules
Ehab Farouk Elkady, Marwa Hosny Tammam & Ayman Abo El maaty
Journal of Liquid Chromatography & Related Technologies  Volume 40, 2017 - Issue 4 Pages 190-198
 
Determination of Glucosamine and Carisoprodol in Pharmaceutical Formulations by LC with Pre-Column Derivatization and UV Detection
Ghada M. Hadad, Randa A. Abdel-Salam, Samy Emara
Journal of Chromatographic Science, Volume 50, Issue 4, April 2012, Pages 307–315

Carisoprodol Impurity B is chemically 5-Methyl-5-propyl-2-dioxanone ; Carbonic acid 2-methyl-2-propyltrimethylene ester. Carisoprodol Impurity B is supplied with detailed characterization data compliant with regulatory guideline. Carisoprodol Impurity B can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Carisoprodol.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.